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Abstract
Background: Secretion of recombinant proteins in yeast can be affected by their improper folding
in the endoplasmic reticulum and subsequent elimination of the misfolded molecules via the
endoplasmic reticulum associated protein degradation pathway. Recombinant proteins can also be
degraded by the vacuolar protease complex. Human urokinase type plasminogen activator (uPA) is
poorly secreted by yeast but the mechanisms interfering with its secretion are largely unknown.
Results: We show that in Hansenula polymorpha overexpression worsens uPA secretion and
stimulates its intracellular aggregation. The absence of the Golgi modifications in accumulated uPA
suggests that aggregation occurs within the endoplasmic reticulum. Deletion analysis has shown
that the N-terminal domains were responsible for poor uPA secretion and propensity to aggregate.
Mutation abolishing N-glycosylation decreased the efficiency of uPA secretion and increased its
aggregation degree. Retention of uPA in the endoplasmic reticulum stimulates its aggregation.
Conclusions: The data obtained demonstrate that defect of uPA secretion in yeast is related to
its retention in the endoplasmic reticulum. Accumulation of uPA within the endoplasmic reticulum
disturbs its proper folding and leads to formation of high molecular weight aggregates.
Background
Though the secretory pathway is organized similarly in
yeast and in other eukaryotic organisms, not all proteins
of higher eukaryotes can be efficiently secreted from yeast
cells. Secretion of some recombinant or mutant proteins
is affected by their improper folding in the yeast endoplas-
mic reticulum (ER) [1,2] and rapid degradation of mis-
folded molecules by cytosolic proteasome complex after
retrograde translocation from the lumenal to cytoplasmic
face of the ER (ER associated protein degradation, ERAD)
[3,4]. Alternatively, misfolded proteins can be sorted from
the late Golgi to vacuole, yeast homologue of lysosome,
and degraded by the vacuolar protease complex [5,6]. The
recognition and retention of misfolded proteins in the ER
is carried out by the "ER quality control" (ERQC) machin-
ery. Saccharomyces cerevisiae differs by the organization of
ERQC not only from higher eukaryotes, but also from
Schizosaccharomyces pombe. However, in spite of these spe-
cies-specific differences, the ERQC involves processing of
the N-linked oligosaccharides in all eukaryotes reflecting
importance of N-glycosylation for protein folding in vivo
[for review, see [7]].
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Human urokinase type plasminogen activator (uPA) is
poorly secreted by yeast. Although three mutations im-
proving uPA secretion in yeast have been characterized
[8–10], the bottleneck for uPA secretion remains uncer-
tain. There are some data indicating that the efficiency of
uPA secretion in yeast depends on the ERQC machinery.
Disruption of the S. cerevisiae PMR1 gene, encoding the
Golgi membrane Ca2+ ion pump, improves uPA secre-
tion, decreases protein glycosylation [8] and causes a de-
fect of the ERAD [11]. The Hansenula polymorpha opu24
mutation with the uPA supersecretion phenotype also im-
pairs protein glycosylation and possibly causes defect of
the ERAD, since, similarly to pmr1, the opu24 mutant is
also hypersensitive to dithiothreitol and tunicamycin,
drugs perturbing protein folding in the ER [10]. However,
the S. cerevisiae ssu21 mutation improving uPA secretion,
does not alter neither glycosylation of secretory proteins
[9], nor sensitivity to dithiothreitol and tunicamycin (M.
Agaphonov, unpublished).
In this study we demonstrate that inefficient uPA secretion
in yeast is related to its retention in the ER that is condi-
tioned by the uPA N-terminal domains. Accumulation of
uPA within the ER affects its folding and leads to forma-
tion of high molecular weight aggregates.
Results
Overexpression of the uPA impairs its secretion and causes 
accumulation in an aggregated form
We have constructed several H. polymorpha strains bearing
different copy numbers of the uPA expression cassette.
This cassette consisted of the uPA gene under the control
of strong regulatable promoter of the H. polymorpha MOX
gene, which encodes a key enzyme of the methanol utili-
zation pathway, alcohol oxidase. In all cases mox-negative
recipients were used for obtaining these transformants
(see Materials and methods). Among them three trans-
formants possessed a single copy of the expression cas-
sette integrated into different genomic loci. The
productivity of extracellular uPA in single copy integrants
varied depending on the integration locus but was always
higher than in strains with multiple copies of the integrat-
ed cassette (Table 1). Immunoblot analysis of cell lysates
revealed that the amount of intracellular uPA grew drasti-
cally with the increase of dosage of the expression cassette,
while uPA activity dropped. This indicates that intracellu-
lar uPA was accumulated mostly in an inactive form.
Further analysis has shown that intracellular uPA accumu-
lated in a form of high molecular weight aggregates, since
it could be precipitated by centrifugation of cell lysates at
10,000 g for 10 min in the presence of a detergent, solubi-
lizing membrane associated proteins (Figure 1B). uPA
from culture supernatants of the single copy integrants
migrated on the SDS PAGE as a broad smear (Figure 2,
lane 3), which could be converted into the distinct ~30
kDa band by treatment with endoglycosidase H (EndoH)
(Figure 2, lane 4). In human cells uPA is synthesized as a
48 kDa zymogen consisting of three domains: two N-ter-
minal domains, not essential for the enzymatic activity,
and the C-terminal serine protease domain (Figure 1A).
uPA zymogen is activated by hydrolysis of the K158-I159
peptide bond. The accuracy of the cleavage is essential for
uPA activation, since hydrolysis of the R156-F157 peptide
bond by thrombin produces inactive protein [for review,
see [12]]. EndoH-treated extracellular uPA migrated faster
than its N-terminally truncated variant lacking the N-gly-
cosylation site (Figure 2, lane 5), indicating that it is a
product of the uPA cleavage at the activation site, because
cleavage at other sites would result in uPA derivatives
showing either different molecular weight or no activity.
Table 1: Dependence of u-PA levels on the copy number and integration locus of the expression cassette.
Copy number in locus: u-PA (%)
Strain mox leu2 telomere activity in culture medium activity in cell lysate amount in cell lysate*
DLU/L 1 100 100 100
DLM/pAM226 1 96 119 98
DLM/pAM219/1 1 68 59 21
DLM/pAM219/2 2 50 49 170
DLU/pAM219 1 1 29 71 560
DLU/pAM226 1 1 17 45 620
DLM/pAM281/1 ~8 10 7 1400
DLM/pAM281/2 ~8 20 7 1100
*Calculated by comparison of intensities of the 50 kDa band revealed by Western blotting of serially diluted cell lysates.BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/15
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In contrast to the extracellular form, intracellular uPA was
core glycosylated, since it migrated on SDS gel as a distinct
band and its electrophoretic mobility only slightly in-
creased after EndoH treatment (Figure 2, lanes 1 and 2).
This means that the N-linked oligosaccharide chain of in-
tracellular uPA had not received the Golgi modifications,
and, therefore, uPA aggregates were formed within the ER.
This conclusion was further confirmed (see below).
Secretion of uPA depends on the presence of N-glycosyla-
tion site and N-terminal domains
In eukaryotic cells uPA is modified by an attachment of
the glycoside chain to the N302 residue. Substitution of
this residue for another one abolishes the N-glycosylation
of uPA [13]. uPA variants with N or Q residue at the posi-
tion 302 in the full-length enzyme (uPA and uPA-Q) or in
its N-terminally truncated form (uPA-C and uPA-CQ)
(Figure 1A) were expressed in H. polymorpha and their
amounts in culture medium were compared with the use
of fibrinolytic activity assay and immunoblotting. These
analyses have shown that both alteration of the N-glyco-
sylation site and presence of the N-terminal domains de-
creases efficiency of uPA secretion (Table 2). The lower
difference in activity of glycosylated and unglycosylated
variants, than it may be deduced from the difference in
amounts of immunoreactive protein can be explained by
the inhibitory effect of the yeast N-glycoside chain on the
specific activity of uPA towards the high molecular weight
substrates [14].
Figure 1
Schematic representation of the uPA variants (A) and Western blot analysis of uPA in subcellular fractions of
transformants expressing different uPA variants (B). Arrows indicate the position of activation cleavage site."Q302"
indicates the mutation abolishing the N-glycosylation of uPA. Transformants DLU, DLC, DLQ and DLCQ, expressing uPA,
uPA-C, uPA-Q and uPA-CQ, respectively, are described in Materials and methods. P and S, pellet and supernatant fractions,
respectively. Pellets were dissolved in a 2-fold volume of starting lysate.
Figure 2
Western blot analysis of uPA in intracellular aggre-
gates and culture medium. Lanes 1 and 2, pellet fraction
of cell lysate of the DLU strain expressing full-length uPA
before and after treatment with EndoH, respectively; lanes 3
and 4, culture medium of the same strain before and after
EndoH treatment, respectively; lane 5, pellet fraction of cell
lysate of the DLCQ strain expressing uPA-CQ.BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/15
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Similar pattern of secretion of different uPA variants was
revealed in the S. cerevisiae integrants carrying a single
copy of the uPA expression cassette (Figure 3), indicating
applicability of the obtained results to different yeast spe-
cies. However, in contrast to H. polymorpha, the transform-
ants of S. cerevisiae bearing the expression cassettes
integrated in a single copy did not accumulate uPA intra-
cellularly. On the other hand, such accumulation took
place in transformants with the multicopy uPA expression
vector (data not shown). Above we demonstrated that in
H. polymorpha high levels of uPA expression, inhibiting se-
cretion, are always accompanied with its intracellular ac-
cumulation (Table 1). Basing on this, we concluded that
uPA expression levels in S. cerevisiae transformants with a
single copy of the uPA expression cassette were lower than
those, which might inhibit its secretion.
Aggregation of uPA is defined by accumulation within the 
ER
Distribution of different uPA variants between the soluble
and pellet fractions obtained by centrifugation of cell
lysates (Figure 1) depended on their secretion potential.
The highest proportion of soluble to aggregated form was
observed for the best secreted uPA variant (uPA-C),
whereas the lowest one was in the case of the worst secret-
ed variant (uPA-Q). Since the major bands of the soluble
fractions of the uPA and uPA-C variants corresponded to
the core-glycosylated protein, they might represent a pool
of newly translocated molecules, whose fate had not been
determined yet, and properly folded molecules, which are
ready to leave the ER or already entered the Golgi appara-
tus, but have not received modifications altering their
electrophoretic mobility.
The amount of uPA in the soluble fraction should depend
on the rates of uPA synthesis, aggregation and exit from
the ER. To prevent the latter process, the uPA and uPA-C
variants were modified by the substitution of 12 C-termi-
nal amino acid residues for the KDEL sequence, represent-
ing the ER retention signal. This should retain in the ER
correctly folded uPA, which is normally secreted, and thus
increase proportion of soluble to aggregated uPA in cell
lysates. Indeed, such modification abolished the exit of
both uPA variants into culture medium (data not shown)
and led to the increase of their amounts in cell lysates,
though this effect was much more pronounced for uPA-C
(Figure 4). Surprisingly, this did not increase the amount
of soluble form of both uPA variants in cell lysates. Since
Table 2: Comparison of secretion efficiencies of different uPA variants by H. polymorpha
Amount in culture medium determined by:
uPA variant Fibrinolytic activity assay (%) Western blotting* (%)
uPA 100 100
uPA-C 1850 1500
uPA-Q 30 14
uPA-CQ 770 330
*Calculated by comparison of intensities of the 30 kDa band revealed by Western blotting of serially diluted culture supernatants. uPA in culture 
medium was treated with EndoH prior to the analysis.
Figure 3
Halo-forming ability of S. cerevisiae (Sc) and H. poly-
morpha (Hp) transformants expressing different uPA
variants. Yeast transformants were patched on fibrin-con-
taining plates and incubated for 20 h (H. polymorpha) or 40 h
(S. cerevisiae).BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/15
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full-length uPA showed a high degree of aggregation on its
own, the addition of the ER retention signal only slightly
increased its aggregation degree. In contrast, the retention
in the ER of uPA-C, which normally is less prone to aggre-
gate, led to a drastic increase of amount of aggregated
form. At the same time amount of the soluble form of uPA
dropped (Figure 4). This indicates that accumulation of
uPA in the ER causes its aggregation.
Accumulation of the wild type uPA in the H. polymorpha
ER may result from its retention in this compartment due
to incorrect folding in the heterologous host. Normally
misfolded proteins in the ER are eliminated by the ERAD
pathway. The data presented in this study suggest that uPA
can partially degrade within the yeast cell. In fact, the rate
of uPA synthesis in the transformant DLU/pAM226, bear-
ing two copies of the expression cassette, must not exceed
more than two-fold the rate of uPA synthesis in the DLU/
L integrant with a single copy of this cassette. However,
the difference in amount of intracellular uPA in these
transformants appeared to be much bigger (Table 1). The
discrepancy between the expected and observed difference
in intracellular accumulation of uPA cannot be explained
by worsening uPA secretion, since in the DLU/L strain the
amount of extracellular enzyme constituted less than 10%
of that of its intracellular form (0.11 g of extracellular
uPA vs. 1.6 g of intracellular uPA per 1 mg of total cellu-
lar protein). Thus, the observed difference in amount of
intracellular uPA probably was due to the degradation of
significant portion of uPA in the transformants with lower
expression levels and rescue of misfolded uPA by aggrega-
tion upon the higher expression levels.
Above it was shown that accumulation of uPA within the
ER causes its aggregation. This means that defect of degra-
dation of uPA in this compartment should increase its
amount and, therefore, the aggregation degree. This sug-
gestion was supported by the results of analysis of the ag-
gregation pattern of uPA-KDEL expressed in the H.
polymorpha opu24 mutant. The uPA supersecretion opu24
mutation has been previously shown to cause phenotypes
characteristic of the ERAD lesion [10]. Impairment of the
ERAD should save misfolded uPA from degradation, thus
increasing its amount within the ER. The amount of aggre-
gated but not soluble form of uPA-KDEL appeared to be
much higher in the mutant than in the wild type cells con-
firming that accumulation of uPA in the ER is accompa-
nied by its aggregation (Figure 5). Interestingly, this
mutation did not noticeably influence the aggregation
pattern of the full-length uPA lacking the ER retention sig-
nal (data not shown). This indicates that accumulation of
wild type uPA within the ER of the mutant cells was not
Figure 4
Distribution of uPA between the supernatant (S) and
pellet (P) fractions of cell lysates. Western blot analysis
of uPA. The lysates of the following transformants were frac-
tionated by centrifugation: DL/pAM226 (uPA), DL/pAM410
(uPA-C), DLpNR4 (uPA-KDEL) and DL/pNR5 (uPA-C-
KDEL). Pellets were dissolved in a 5-fold volume of starting
lysate.
Figure 5
The aggregation pattern of uPA-KDEL in the opu24
mutant. Western blot analysis of uPA. S and P, the superna-
tant and pellet fractions of the cell lysates of 24–8 V/pNR4
(opu24) and 8 V/pNR4 (OPU24) strains. Pellets were dis-
solved in a 100-fold volume of starting lysate.BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/15
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accelerated though degradation of misfolded protein was
impaired. Thus, it is possible to suggest that this mutation
facilitates exit of uPA from the ER probably due to the ac-
tivation of mechanisms improving efficiency of its fold-
ing.
Discussion
The data obtained show that efficient uPA secretion de-
mands an optimal level of its expression: both low and in-
creased expression did not result in the maximal levels of
uPA secretion. Indeed, we observed that the best uPA se-
creting strains were those containing the uPA expression
cassette integrated in a single copy into the MOX or LEU2
genes. In contrast, integrants carrying a single copy of the
uPA cassette integrated into a telomere region produced
less uPA and were less efficient in uPA secretion. On the
other hand, strains with multiple copies of the integrated
cassette also secreted less uPA and accumulated it in an in-
active form intracellularly. Comparison of strains with
uPA expression exceeding an optimal level showed an in-
verted correlation between the efficiency of its expression
and secretion (Table 1). This can explain why no mutants
with increased uPA expression levels were obtained so far
among those producing more of its extracellular form.
We also found that upon overexpression uPA is accumu-
lated in a form of high molecular weight aggregates. The
absence of the Golgi modifications in accumulated uPA
suggested that its aggregation occurred within the ER. De-
letion analysis has shown that the N-terminal domains of
uPA were responsible for the elevated levels of its aggrega-
tion. Alteration of the N-glycosylation site of uPA also re-
sulted in its intracellular accumulation and aggregation.
Thus, it is possible to suggest that both the presence of N-
terminal domains and the absence of N-glycosylation
caused intracellular accumulation of uPA, which inter-
fered with its proper folding and resulted in subsequent
aggregation in the ER. In agreement with this, the presence
of the ER retention signal significantly increased aggrega-
tion degree of the best secreted uPA variant lacking the N-
terminal domains.
Some of the ERAD substrates, e. g. mutant carboxy pepti-
dase Y, can escape degradation and accumulate within the
ER if they lack the N-linked oligosaccharide chains [15].
Thus, it is possible that the misfolded uPA variants lacking
the N-glycosylation site also escape degradation and accu-
mulate in the ER, interfering with the folding of newly
synthesised molecules due to the "crowding" effect. This
may explain why these uPA variants demonstrated worse
secretion and higher propensity to aggregate.
The aggregation of uPA on its own is unlikely to be the
cause of its poor secretion by yeast cells, since transform-
ants bearing a single copy of the uPA expression cassette
integrated into the MOX or LEU2 loci showed both higher
secretion rate of uPA and higher degree of its aggregation,
than transformant with a single copy of this cassette inte-
grated into a telomere region. Moreover, it is possible that
to some extent, the aggregation of uPA even improves its
secretion: accumulation in aggregates may decrease uPA
crowding in the ER, thus facilitating its proper folding and
subsequent secretion.
The increased aggregation of uPA-KDEL in the H. polymor-
pha opu24 mutant provides an additional evidence for the
interference of uPA accumulation within the ER with its
folding. We suggest that the degradation rate of uPA-
KDEL in this mutant was reduced due to the ERAD lesion.
In contrast, the opu24 mutation did not stimulate aggrega-
tion of uPA lacking the ER retention signal. This indicates
that a significant portion of uPA escaped from the ER,
probably due to improved folding, which may be the rea-
son of the "supersecretion" phenotype of this mutant.
Conclusions
In this work we demonstrate that in H. polymorpha overex-
pression poisons uPA secretion and stimulates its intracel-
lular aggregation. The absence of the Golgi modifications
in accumulated uPA suggests that the aggregation occurs
within the ER. Deletion analysis has shown that the N-ter-
minal domains of uPA were responsible for its poor secre-
tion and propensity to aggregate. Mutation abolishing N-
glycosylation decreased the efficiency of uPA secretion
and increased its aggregation degree. Retention of uPA in
the ER by means of the KDEL signal also led to its accumu-
lation in an aggregated, but not in soluble form, and the
amount of uPA-KDEL aggregates increased in the opu24
mutant with defects in the ER-associated degradation of
misfolded proteins. These experiments demonstrate that
the increase of uPA content in the yeast ER interferes with
its folding. The data obtained in this work allow us to sug-
gest that uPA is poorly secreted by yeast, because its fold-
ing requires milieu of the ER of higher eukaryotes. The
unfavorable milieu in the yeast ER causes incorrect fold-
ing of significant portion of uPA, which is retained in the
ER and undergoes either degradation or aggregation.
Methods
Yeast strains
The H. polymorpha strains DL1-L (leu2) derived from DL-1
(ATCC 26012), 8 V (leu2) and 24–8 V (opu24 leu2) de-
rived from CBS4732 (ATCC 34438) were described earlier
[10,16,17]. The trp3 mutant DLT2 (leu2 mox, trp3::LEU2)
was obtained by transformation of the DL1-L strain with
the plasmid pMLT, digested with XhoI and Ecl136II as
described earlier [18]. The DL1-LM strain (leu2 mox)
was obtained by transformation of DLT2 with the XhoI
and Ecl136II digested plasmid pSM. The cassettes ex-
pressing different variants of uPA were introduced into theBMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/15
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H. polymorpha genome either by replacement of the MOX
gene [18], or via single copy integration of the expression
vectors possessing the HpLEU2-d selectable marker into
the LEU2 locus [19]. The uPA expressing transformants
are listed in Table 3. Integration into the MOX locus was
performed via transformation of the DLT2 strain with the
plasmids pSM1, pUR2SM1, pSMWC or pSMWCQ, digest-
ed with XhoI and Ecl136II. Integration into the LEU2 locus
was performed via transformation of the leu2 strains with
the plasmids pAM226, pAM410, pNR4 or pNR5, digested
with Ecl136II. The S. cerevisiae strains expressing different
uPA variants were obtained via integration of the EcoRV-
digested expression vectors pNR9, pNR23, pNR26 and
pNR27 into the URA3 locus of the YPH499 strain [20].
Plasmids
The plasmids used in this study are listed in Table 4. The
uPA expression vectors pAM219, pAM226 and pAM281
were constructed by the insertion of sequence encoding
uPA fused to the signal peptide of the Kluyveromyces lactis
killer toxin [21] under control of the MOX promoter into
the BamHI and HindIII sites of the AMIpL1, AMIpLD1 and
AMIpSL shuttle vectors [19], respectively. This insert con-
sisted of a 1.8 kb XhoI-BamHI fragment of the pSM1 plas-
mid [18] and an adapter, which was obtained by
annealing the oligonucleotides
5'GATCCGCAGTCACACCAAGGAAGAGAATGGCCTGG
CCCTCTGA3' and
5'AGCTTCAGAGGGCCAGGCCATTCTCTTCCTTGGTGT
GACTGCG3'. To allow ligation of the BamHI cohesive end
of these vectors and the XhoI cohesive end of the insert,
two bp of their overhangs were filled in by the Klenow en-
zyme. The expression vectors pAM410 and pSMWC en-
coding the N-terminally truncated uPA were constructed
by insertion of a 0.8 kb BglI-BamHI fragment of pWC28
(kindly given by M. Minashkin), carrying the sequence en-
coding uPA protease domain, into the KpnI and BamHI
sites of the pAM226 and pSM1 plasmids, respectively (3'-
terminal overhangs of KpnI and BglI were removed by the
Klenow enzyme). The plasmid pSMWCQ was constructed
by replacement of the 0.7 kb BamHI-EcoRI fragment of
pSMWC for the corresponding fragment of pUR2SM [10].
The expression vectors pNR4 and pNR5 encoding uPA
variants with the KDEL ER retention signal were construct-
ed by the insertion of an adapter, which was obtained by
annealing the oligonucleotides
5'GATCAAGGACGAGCTGT3' and
5'AGCTACAGCTCGTCCTT3', between the BamHI and
HindIII sites of pAM226 and pAM410.
The S. cerevisiae uPA expression vectors were based on the
YIpSEC-NR8 integrative shuttle vector, which was ob-
tained from the YEpSEC1 plasmid [21] by deletion of the
SnaBI-AatII fragment, carrying the 2 m DNA sequence
and the LEU2 gene. The wild type uPA expression vector
pNR9 was constructed by insertion of the 1.2 kb KpnI-Hin-
dIII fragment of the pAM226 plasmid into the corre-
sponding sites of the YIpSEC-NR8 plasmid. The uPA-C
expression vector pNR23 was obtained by replacement of
the KpnI-BamHI fragment in the pNR9 plasmid for the
BglI-BamHI fragment of the pWC28 plasmid (3'-terminal
overhangs of KpnI and BglI were removed by the Klenow
enzyme). The uPA-Q and uPA-CQ expression vectors
pNR26 and pNR27 were obtained by replacement of the
EcoRI-BamHI fragment in the plasmids pNR9 and pNR23
for the corresponding fragment of pUR2SM.
Culture conditions
Culture conditions for the H. polymorpha strains and con-
ditions for the induction of uPA expression in the
CBS4732 derivatives were described previously [19]. To
induce uPA expression in transformants of the DL1-L
strain, overnight YPD cultures were 6-fold diluted with
YPM medium (2% Peptone, 1% Yeast extract, 2.5% meth-
anol, 150 mM NaCl) and incubated at 37C for 50–60 h.
Analyses of uPA expression
To prepare lysates, cells were disrupted with glass beads in
TBST buffer (30 mM tris-HCl pH7.5, 150 mM NaCl, 2%
Triton  100), containing protease inhibitors, 1 mM phe-
nylmethylsulfonyl fluoride (PMSF), 0.1 mM benzami-
dine, 0.1 mM sodium metabisulphite, 0.5 g/ml TPCK,
0.5 g/ml TLCK, 2.5 g/ml antipain, 0.5 g/ml leupep-
tine, 1.0 g/ml pepstatin A, 2.0 g/ml aprotinine. The pro-
tease inhibitors were omitted if lysates were analyzed for
the uPA activity. Amounts of active uPA were determined
by fibrinolytic activity assay [22]. Total amounts of uPA in
cell lysates and culture medium of different transformants
were compared by probing appropriately diluted lysates
and culture supernatants with the anti-uPA antibody spe-
cific to the uPA protease domain [23]. The amounts of u-
PA in culture medium were normalized to the levels of to-
tal cellular protein [24], whereas amounts of u-PA from
cell lysates were normalized to the levels of soluble cellu-
lar protein in a sample assayed as described [25]. To study
uPA aggregation, cell debris was removed from lysates by
centrifugation at 300 g for 10 min and lysates were centri-
fuged again at 10,000 g for 10 min. Obtained pellet and
supernatant fractions were analyzed by Western blotting.
A qualitative test for the ability of yeast transformants to
secrete uPA was performed by examination of their capac-
ity to create haloes during growth on fibrin-containing
media, as described previously [9,18].
Transformation of H. polymorpha and Escherichia coli 
cells
H. polymorpha was transformed by the modified lithium
acetate method [26]. E. coli was transformed as described
[27].BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/15
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